Other equities analysts have also recently issued reports about the company. Piper Jaffray Companies reissued a “buy” rating and set a $104.00 target price on shares of Crispr Therapeutics in a research note on Tuesday, November 26th. ValuEngine raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Canaccord Genuity increased their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research report on Wednesday, November 20th. Roth Capital upped their price target on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Finally, Oppenheimer upped their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the stock. Crispr Therapeutics presently has an average rating of “Buy” and a consensus price target of $69.54.
Shares of NASDAQ:CRSP opened at $68.06 on Friday. The company’s fifty day moving average is $62.13 and its 200 day moving average is $49.47. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, sell-side analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 in the last 90 days. Company insiders own 21.40% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC raised its holdings in Crispr Therapeutics by 5.9% during the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock valued at $839,000 after acquiring an additional 986 shares during the period. Nikko Asset Management Americas Inc. lifted its holdings in Crispr Therapeutics by 324.3% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after purchasing an additional 1,430,364 shares in the last quarter. BNP Paribas Arbitrage SA purchased a new stake in Crispr Therapeutics during the 2nd quarter valued at approximately $41,000. ARK Investment Management LLC raised its position in shares of Crispr Therapeutics by 34.7% during the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after buying an additional 701,332 shares during the last quarter. Finally, Aperio Group LLC purchased a new position in shares of Crispr Therapeutics in the second quarter worth $153,000. 49.82% of the stock is owned by hedge funds and other institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: What is a Call Option?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.